Actively Recruiting

All Genders
NCT07185919

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

Led by Ipsen · Updated on 2026-04-30

10

Participants Needed

3

Research Sites

361 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will collect information from people with Progressive Familial Intrahepatic Cholestasis (PFIC) as they use odevixibat in their daily lives. Odevixibat is a medicine that helps people with PFIC, a type of rare disease that makes their liver not work well and causes itching and yellow skin. Odevixibat was first allowed to be used for PFIC in babies older than 6 months by the European Medicines Agency (EMA) on 16 July 2021 and by the United States Food and Drug Administration (FDA) on 20 July 2021 for itching in babies older than 3 months. Obevixibat was approved by the Ministry of Food and Drug Safety (MFDS) in South Korea on 23 August 2024. This study will collect information to see how well and how safe odevixibat is in the long run for participants in South Korea.

CONDITIONS

Official Title

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Progressive Familial Intrahepatic Cholestasis (PFIC) of any type and prescribed odevixibat by their doctor
  • Currently taking or starting active treatment with odevixibat
  • May remain in the registry even if odevixibat treatment is temporarily stopped
Not Eligible

You will not qualify if you...

  • Currently participating in a clinical trial involving odevixibat
  • Currently participating in any other interventional clinical trial for PFIC
  • Have any contraindications to odevixibat according to the approved label in South Korea

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Pusan National University Yangsan Hospital

Gyeongsang, South Korea

Active, Not Recruiting

2

Seoul National University Hospital

Seoul, South Korea

Not Yet Recruiting

3

Severance Hospital, Yonsei University Health System

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

I

Ipsen Clinical Study Enquiries

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here